According to the Zhitong Finance App, Dongyangyang Pharmaceutical (06887.HK) announced that the Degumendong Double Insulin Injection developed independently by the Group was officially approved for marketing by the China National Drug Administration (NMPA), covering both types of refills and pre-filled injection pens.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.